World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 8 November 2021
Main ID:  EUCTR2016-003523-34-HU
Date of registration: 31/01/2017
Prospective Registration: Yes
Primary sponsor: Ra Pharmaceuticals, Inc.
Public title: Extension Study of RA101495 in Paroxysmal Nocturnal Haemoglobinuria (PNH)
Scientific title: A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Date of first enrolment: 17/03/2017
Target sample size: 28
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003523-34
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Australia Denmark Finland Germany Hungary New Zealand United Kingdom United States
Contacts
Name: xx   
Address:  87 Cambridge Park Drive MA 02140 Cambridge United States
Telephone: +16174014060
Email: trials@rapharma.com
Affiliation:  Ra Pharmaceuticals, Inc.
Name: xx   
Address:  87 Cambridge Park Drive MA 02140 Cambridge United States
Telephone: +16174014060
Email: trials@rapharma.com
Affiliation:  Ra Pharmaceuticals, Inc.
Key inclusion & exclusion criteria
Inclusion criteria:
Male or female > 18 years having completed a qualifying RA101495 clinical study and met predefined criteria for extended treatment with RA101495
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 8

Exclusion criteria:
1. Platelet count <30,000/µL or absolute neutrophil count (ANC) <500 cells/µL at Screening
2. Caluculated glomerular filtration rate of <30 mL/min/1.73m2 based on modification of diet in renal disease (MDRD) equation at Screening
5. History of meningococcal disease
6. Current systemic infection or suspicion of active bacterial infection
7. Pregnant, planning to become pregnant, or nursing female subjects



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Paroxysmal Nocturnal Haemoglobinuria (PNH)
MedDRA version: 20.0 Level: LLT Classification code 10055629 Term: Paroxysmal nocturnal hemoglobinuria System Organ Class: 100000012950
Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Intervention(s)

Product Name: RA101495
Product Code: RA101495
Pharmaceutical Form: Solution for injection
INN or Proposed INN: RA101495 sodium
CAS Number: 1841136-73-9
Current Sponsor code: RA101495
Other descriptive name: Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 40-

Primary Outcome(s)
Primary end point(s): Adverse Events and Serious Adverse Events profile including major adverse vascular event (MAVE criteria), clinical laboratory tests, ECGs, vital signs, physical examinations, and determination of anti-drug antibodies (ADA).
Timepoint(s) of evaluation of this end point: At each study visit (Month 1, 2, 3, 6, 9, 12, then every 3 months).
Main Objective: • To provide access to RA101495 for subjects with PNH who have who have completed a Ra Pharmaceuticals sponsored study, have demonstrated clinical benefit, and who wish to continue receiving RA101495 for treatment of PNH
• To evaluate the long-term safety and tolerability of RA101495 administered to subjects with PNH who have completed a Ra Pharmaceuticals sponsored RA101495 clinical study
• To evaluate the long-term preliminary efficacy of RA101495 administered to subjects with PNH who have completed a Ra Pharmaceuticals sponsored RA101495 clinical study
• To obtain periodic PK and PD data to confirm long-term maintenance of steady-state RA101495 plasma levels and sustained inhibition of hemolysis and complement
Secondary Objective: N/A
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: Not applicable
Secondary end point(s): Not applicable
Secondary ID(s)
2016-003523-34-FI
RA101495-01.202
Source(s) of Monetary Support
Ra Pharmaceuticals, Inc.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 06/03/2017
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history